Ambrx Biopharma Inc. operates as a clinical-stage biologics company. The company is headquartered in La Jolla, California and currently employs 66 full-time employees. The company went IPO on 2021-06-18. The company is focused on discovering and developing a novel class of engineered precision biologics, using its expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids (SAAs), into proteins within living cells. Its product candidates are designed to overcome the inherent limitations of conventional conjugation approaches that use natural amino acids for non-site-specific conjugation, offering potential safety and benefits to treat patients across multiple therapeutic areas. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as antibody-drug conjugates (ADCs), immuno-oncology conjugate, bispecific antibodies, PEGylated peptides, modified cytokines and immuno-stimulating antibody conjugates. Its lead ADC product candidates in clinical development: ARX788 and ARX517. ARX517 is an anti-prostate-specific membrane antigen.

Industry: Biological Products, (No Diagnostic Substances) Peers: Aligos Therapeutics Inc Athenex, Inc. Beyondspring Inc Perspective Therapeutics Inc Cidara Therapeutics, Inc. Sellas Life Sciences Group Inc Oncternal Therapeutics, Inc. IN8bio Inc Rubius Therapeutics, Inc.